PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Nelson, David R.
TI  - Combination DCV/SOF is Effective in Achieving Sustained Response in Patients with HCV GT-3
DP  - 2014  01
TA  - MD Conference Express
PG  - 12--13
VI  - 14
IP  - 48
4099  - http://mdc.sagepub.com/content/14/48/12.short
4100  - http://mdc.sagepub.com/content/14/48/12.full
AB  - Hepatitis C virus genotype (GT)-3 is common worldwide and is accompanied by a significant disease burden. Among patients with cirrhosis, it is associated with increased risk of fibrosis progression, steatosis, and hepatocellular carcinoma. The Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV [ALLY-3; NCT02032901] trial evaluated the efficacy and safety of daclatasvir plus sofosbuvir in patients chronically infected with GT-3.